Drug intelligence / Profile preview

ZYG24002

Development stage: Phase 1
Lead developer: Sinomune Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

ZYG24002 is a topical small molecule Janus kinase (JAK) inhibitor developed by Sinomune Pharmaceutical Co., Ltd. for the treatment of inflammatory skin conditions, primarily seborrheic dermatitis. By targeting the JAK-STAT signaling pathway, ZYG24002 aims to modulate the immune response and reduce the production of pro-inflammatory cytokines that drive the pathogenesis of seborrheic dermatitis, such as erythema and scaling. The drug is currently being evaluated in Phase 1b clinical trials (e.g., NCT06344104) as a lotion in various concentrations (0.5%, 0.75%, and 1.0%) to establish its safety, tolerability, pharmacokinetics, and preliminary efficacy in adult patients with mild to moderate disease.

Other names: ZYG24002 LotionZYG-24002 LotionZYG 24002 Lotion

Targets

JAK (Janus kinase family)

Beyond the preview

Go deeper on ZYG24002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYG24002.

Explore the full profile